Join Growin Stock Community!

Vicarious surgical inc.RBOT.US Overview

US StockHealthcare
(No presentation for RBOT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

RBOT AI Insights

RBOT Overall Performance

RBOT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RBOT Recent Performance

-2.94%

Vicarious surgical inc.

0.05%

Avg of Sector

-0.31%

S&P500

RBOT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

RBOT Key Information

RBOT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

RBOT Profile

Vicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. It offers Vicarious System, a single-incision surgical robot for ventral hernia repair. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Price of RBOT

RBOT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RBOT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-8.29
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.03
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-8.29
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.03
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is RBOT's latest earnings report released?

    The most recent financial report for Vicarious surgical inc. (RBOT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RBOT's short-term business performance and financial health. For the latest updates on RBOT's earnings releases, visit this page regularly.

  • How much debt does RBOT have?

    As of the end of the reporting period, Vicarious surgical inc. (RBOT) had total debt of 12.89M, with a debt ratio of 0.44. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does RBOT have?

    At the end of the period, Vicarious surgical inc. (RBOT) held Total Cash and Cash Equivalents of 4.1M, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is RBOT's EPS continuing to grow?

    According to the past four quarterly reports, Vicarious surgical inc. (RBOT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.86. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of RBOT?

    Vicarious surgical inc. (RBOT)'s Free Cash Flow (FCF) for the period is -10.58M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 16.41% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.